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ABSTRACT 
The aim of the work was to check the therapeutic effect of L-arginine for liver cell regeneration. L-arginine is a semi-essential amino acid works 
as a nitric oxide precursor. Sustained released matrix beads of L- arginine were developed and tested for its hepatoprotective effect in rats 
(paracetamol was used to induce liver toxicity). Various biochemical tests of hepatic damage like SGPT, SGOT, ALP and bilirubin were done in 
all groups of animals. A toxic dose of paracetamol enhanced the SGPT, SGOT, ALP and bilirubin levels followed by treatment with silymarin as 
standard and L-arginine as test drugs. Histopathological studies also supported the hepatoprotective effect, containing L-arginine.Animal group 
treated with L-arginine indicated a significant decrease in the levels of biochemical markers to the near normal levels. The liver section o f 
toxicant animals showed degenerative changes, aggregates of mononuclear inflammatory cells while treatment with formulations containing L -
arginine helped in regaining the normal hepatic architecture, hence it can be concluded that significant effect of L-arginine was observed in liver 
cell regeneration. 
Keywords: Hepatoprotective, L-arginine, Silymarin, SGPT, SGOT. 
 
Article Info: Received 16 May 2019;     Review Completed 27 June 2019;     Accepted 03 July 2019;     Available online 15 July 2019 
Cite this article as: 
Sharma V, Singh L, Shrivastav A, Verma N, Effect of L-arginine amino acid on liver regeneration after hepatocyte damage 
in rats: An experimental study., Journal of Drug Delivery and Therapeutics. 2019; 9(4):470-476   
http://dx.doi.org/10.22270/jddt.v9i4.3182                                                           
*Address for Correspondence:   
Vijay Sharma, Pharmacy Academy, IFTM University, Moradabad, UP, India 
 
 
INTRODUCTION 
The Liver is the largest vital organ in the body. In human 
being it is separated incompletely into lobes, covered on 
their external surfaces by a thin connective tissue capsule. 
Major functions of the liver are metabolism and 
detoxification of hepato-toxic substances which can cause 
damage to the liver during metabolic reactions 1. Liver 
diseases, including hepatitis B virus and hepatitis C virus 
infections, alcoholic liver disease, nonalcoholic fatty liver 
disease  and associated cirrhosis, liver failure and 
hepatocellular carcinoma, are major causes of illness and 
death worldwide 2. It has been reported that liver diseases 
have become a global problem and about 20,000 deaths 
has been reported every year due to liver disorders 3. 
Arginine is a semi-essential amino acid involved in 
multiple areas of human physiology and metabolism. Nitric 
Oxide produced from arginine is helpful in improving 
outcomes in various diseases. L-arginine is readily 
available over the counter and is popular as a nutritional 
supplement. Several researches has been proved that L-
arginine had a therapeutic effect in numerous acute and 
chronic disease states, including sickle cell chest crisis, 
pulmonary artery hypertension, coronary heart disease, 
pre myocardial infarction. Hence present work was aimed 
to determine the effect of L-arginine on liver regeneration 
after hepatocyte damage in rats. 
MATERIALS AND METHODS 
L-Arginine was purchased from SD Fine Chemicals Ltd. 
India, paracetamol from Sigma-Alderich Ltd. India, 
Silymarin form Sigma Chemical Co., India were purchased 
from the local supplier. Diagnostic kits for the estimation 
of SGOT, SGPT, SALKP, and serum bilirubin were 
purchased from a local supplier (Sai chemicals, India). 
Animals used 
Animals Studies were carried out using Wistar albino rats 
(150-180 g) of either sex. They were obtained from the 
animal house, Indian Veterinary Research institute (IVRI), 
Bareilly, India. The animals were grouped and kept in poly 
acrylic cages with not more than six animals per cage and 
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maintained under standard laboratory conditions 
(temperature 25 ± 2°C) with dark and light cycle (14/10 
hr). They were allowed free access to standard dry pellet 
diet and water. The rats were acclimatized to laboratory 
condition for 10 days before commencement of the 
experiment. All procedures described were reviewed and 
approved by the Animal ethical Committee (CPCSEA 
registration number: 715/PO/Re/S/02/CPCSEA). 
Preparation of Microbeads 
The microbeads were prepared by using ionic gelation 
method as mentioned in previous work of formulation 
development 4. SA solution (4 % w/v) was prepared by 
dissolving 8 g of SA in small amount distilled water in a 
mortar pestle. When a clear solution was formed, the 
volume made up to 100 mL. L-Arginine was added into SA 
solution with 15 m stirring on magnetic stirrer to form a 
clear solution. Chitosan (0.5%) and calcium chloride (6%) 
were dissolved in 1% acetic acid solution. The pH of the 
solution was adjusted to 5 using a 0.1 N NaOH solution and 
was stirred for a further 30 min. Drug containing SA 
solution was then dropped drop wise through 21 gauge 
needle into 100 mL solution of CC solution and microbeads 
were formed. The gelation time of 30 m was allowed to 
complete the curing reaction in the CC solution containing 
chitosan and then microbeads were collected, filtered 
through wattman filter paper and washed thoroughly with 
water 5, 6. 
Paracetamol-induced liver damage in rats 
The rats were randomly distributed in five groups (six rats 
in each group): 
Group I (control group): received a normal diet. 
Group II (Paracetamol-intoxicated group): received 
Paracetamol 1000 mg/kg of body weight in distilled water 
to induce hepatotoxicity and received no other treatment 
which is severed as a positive control.  
Group III (protection group): Received Paracetamol 
1000 mg/kg (1 ml tween/kg body weight) of body weight 
in 1ml of distilled water. After confirmation of 
hepatotoxicity, animals were treated orally with pure L-
arginine (100 mg/kg of body weight).  
Group IV (curative group): Received Paracetamol 1000 
mg/kg of body weight in 1ml of distilled water. After 
confirmation of hepatotoxicity, animals were treated orally 
with prepared L-arginine loaded alginate microbeads 
(equivalent to 50 mg/kg of body weight). 
Group IV (curative group): Received Paracetamol 1000 
mg/kg of body weight in 1ml of distilled water. After 
confirmation of hepatotoxicity, animals were treated orally 
with prepared L-arginine loaded alginate microbeads 
(equivalent to 100 mg/kg of body weight). 
Prepared formulations were administered by oral route 
using a plastic catheter. 
Biochemical studies  
The blood was obtained from all animals by puncturing 
retro-orbital plexsus. The blood samples were allowed to 
clot for 45 min at room temperature. Serum was separated 
by centrifugation at 2500 rpm at 30°C for 15 min and 
utilized for the estimation of various bio-bio-chemical 
parameters namely SGPT and SGOT 7,8. 
 
 
Estimation of Transaminase 
Serum Glutamate Pyruvate Transaminase (SGPT)  
The SGPT catalyzes the transfer of an amino group from L - 
Alanine to L - Katogthta rate with the formation of 
Pyruvate and glutamate at a pH 7.4. The pyruvate so 
formed is allowed to react with 2, 4 DWPH to produce 2:4 
definitionPhenylehydrazonederivative which is brown 
colored in alkaline Medium. The absorbance of this 
hydrazone derivative is correlated to SGPT activity by 
plotting a Calibration curve using Pyruvate 9,10. 
Serum Glutamate Oxaloacetate Transaminase (SGOT) 
SGOT Catalyzes transfer of an amino group from L. 
aspartate to L - Kalogluterate with the formation of 
Oxaloacetate and glutamate. The Oxaloacetate so formed, is 
allowed to react with 2, 4, DNPH to form 2: 4 
dinitroPhenylehydrazone derivative which is brown 
colored is alkaline medium. The absorbance of this 
hydrazone derivative is correlated to SGOT activity by 
plotting a calibration curve using pyruvate standard 9, 10. 
Estimation of Serum Alkaline Phosphatase (SALP) 
Serum SALP hydrolyzes phenyl phosphate into phenol and 
disodium hydrogen phosphate at OH 10.0. The phenol so 
formed acts with 4-Aminoantipyrine in alkaline medium in 
presence of oxidizing agent potassium ferricyanide to form 
a red colored complex whose absorbance is proportionate 
to the enzyme activity 11,12. 
Estimation of Total Bilirubin  
Bilirubin reacts will diazotize sulfanilic acid in acidic 
medium to form azobilirubin, a purple colored complex 
whose absorbance is proportional to bilirubin 
concentration. The total bilirubin (Direct and Indirect) the 
diazotization is carried out in the presence of an 
activator13. Direct bilirubin, being water soluble is allowed 
to react with diazotized sulfuric acid in the absence of an 
activator. 
Liver Weight and Volume  
The liver was carefully excised and washed in ice-cold 
normal saline solution and pressed between filter paper 
pads and weighed. A portion of the liver (one animal of 
each group) was preserved in 10% neutral formalin for 
histopathology studies 14 
Histopathological Studies  
On the eight day surviving animals from each group were 
sacrificed by decapitation and the histopathologic 
techniques 15. The liver was carefully dissected out, 
extraneous tissue was cleaned off and then wet weight and 
volume were noted. The Part of the liver was fixed in 
formol-saline and processed for microtome sectioning at 5-
micron thickness, stained with harmatoxylin and eosin. 
The damaged produced in the liver structure in the form of 
degeneration, necrosis and fibrosis was graded 16. 
Statistical methods employed  
To achieve a meaningful conclusion the data were analysed 
by standard statistical procedures Snedecor and Cochran 
(1967). Average and standard errors were calculated at 
different days after treatment and also in different 
treatment groups, for each of the parameter studied. In 
order to investigate the effect of days of treatment (0 - 7 
days) as well as the effect of the treatment groups on 
different biochemical constituents and enzymes one way 
ANOVA was carried out Whenever an effect was found to 
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be significant the critical difference (CD) test were carried 
out in order to compare the subclass means for 
significance. All experiments were repeated for three 
times. Results are reported as means ± S.E.M. ANOVA was 
used to evaluate differences between groups. P < 0.05 
considered as significant.  
RESULTS 
Biochemical studies 
Estimation of Transaminase (Serum Glutamate 
Pyruvate Transaminase) 
(A) Control set 
The SGPT activity in group1 (normal) was recorded to be 
84.17 ± 6.20 IU/L 
 (B) Test set 
SGPT activity after administration of paracetamol 500 
mg/kg for 7 days was found to be 268.92. ± 2.32 IU/L 
while 78.23± 4.20; 96.04± 4.77 and 85.44± 5.12 IU/L 
respectively for group 3, 4 &5 (table 1 & figure 1). 
Serum Glutamate Oxaloacetate Transaminase 
(A) Control set 
The SGOT activity in group1 (normal) was recorded to be 
355.92. ± 1.65 IU/L. 
(B) Test set 
SGOT activity after administration of paracetamol 500 
mg/kg for 7 days was found to be 465.92. ± 5.11 IU/L 
while 380.51.± 4.65; 393.65.± 4.45 and 386.42 ± 4.78 IU/L 
respectively for group 3, 4 &5 (table 1 & figure 1). 
 
Fig. 1: SGPT and SGOT level of various groups 
Serum Alkaline Phosphate (SALP) 
(A) Control set 
The mean serum alkaline phosphate (SALP) of group1 
(normal) was recorded to be 159.74±6.21IU/L. 
 (B) Test set 
After administration of paracetamol 500 mg/kg for 7 days 
serum alkaline phosphate (SALP) was found to be 485.22 ± 
7.10 IU/L while 315.77 ± 5.65; 336.25 ± 5.33and 322.53 ± 
4.96 IU/L respectively for group 3, 4 &5 (table 1 & figure 
2). 
 
Fig. 2: Serum albumin phosphate of various groups 
Data are expressed as mean ± S.E.M from six rats and 
analyze by one way ANOVA followed by Tukey tests. 
*P<0.05, **P<0.01 as compared to normal group animals 
Total Serum Bilirubin  
The results of total serum bilirubin in group1, 2, 3, 4 & 5 
have been depicted in table 6.1. The unit is expressed in 
mg/dL. 
(A) Control set 
The mean total serum bilirubin of group 1(normal) was 
recorded to be 0.41 ± 0.2o mg/dL. 
 (B) Test set 
After administration of paracetamol 500 mg/kg for 7 days 
total serum bilirubin was found to be 7.22 ± 11.12 mg/dL 
while 0.45 ± 0.09; 0.35 ± 0.21 and 0.32 ± 0.13mg/dL 
respectively for group 3,4&5. 
Data are expressed as mean ± S.E.M from six rats and 
analyze by one way ANOVA followed by Tukey tests. 
*P<0.05, **P<0.01 as compared to normal group animals
 
 
Fig. 3: Total serum bilirubin group of various groups 
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Table 1: Effect of L-arginine on serum parameters for paracetamol induced hepatotoxicity 
Groups SGPT(IU/L) SGOT(IU/L) SALP(IU/L) 
T
o
ta
l 
b
il
ir
u
b
in
 
(m
g
/d
L
) 
Liver weight  
(mg/100gm body 
weight) 
G
ro
u
p
 1
 
 Normal 84.17 ± 6.20 355.92. ± 1.65 159.74±6.21 0.41±0.20 3.435±0.134 
G
ro
u
p
 2
 
 
Paracetamol; 
(500mg/kg) 
268.92. ± 2.32 465.92. ± 5.11 485.22 ± 7.10 2.22 ± 11.12 4.693±0.122 
G
ro
u
p
 3
 
 
Silymarin + 
Paracetamol 
(100 mg/kg 
p.o.) 
78.23± 4.20** 380.51. ± 4.65** 315.77 ± 5.65** 0.45 ± 0.09** 3.785±0.210** 
G
ro
u
p
 4
 
 
L-arginine + 
Paracetamol 
(50mg/kg) 
96.04± 4.77* 393.65. ± 4.45* 336.25 ± 5.33* 0.47 ± 0.21* 4.005±0.105* 
G
ro
u
p
 5
 
 
L-arginine + 
Paracetamol 
(100mg/kg) 
85.44± 5.12** 386.42 ± 4.78** 322.53 ± 4.96** 0.32 ± 0.13 3.86±1.021** 
Data are expressed as mean ± S.E.M from six rats and analyze by one way ANOVA followed by Tukey tests. *P<0.05, **P<0.01 as 
compared to normal group animals. Serum Glutamate Pyruvate Transaminase (SGPT), Serum Glutamate Oxaloacetate 
Transaminase (SGOT),  Estimation of Serum Alkaline Phosphatase (SALP) 
Histopathology Studies  
Histological samples were categorized based on the extent 
of hepatic injuries like necrosis, inflammation, fibrosis, 
vascular characteristics and overall injury (figure 4-8) 17. 
The results of histopathological studies of normal rat liver 
showed normal hepatocytes, sinusoids in control group 
(Group 1.). Liver section of rat treated with Paracetamol 
exhibited severe necrosis, disappearance of hepatocytes 
and areas of inflammation with increased sinusoidal 
spaces.  
Liver section of rat treated with Arginine (50mg) and 
paracetamol exhibited mild degree of necrosis, reduced 
sinusoidal dilation and less inflammation in group 4. Liver 
section of rat treated with arginine (100mg) and 
paracetamol showed normal hepatocyte appearance with 
normal sinusoids with no inflammation in group 5. Liver 
section of rat treated with silymarin (100mg) and 
paracetamol exhibited normal hepatocytes in group 3. The 
results are given in Fig. 4 to 8. 
 
Fig. 4: Histopathological photomicrograph in the experimental rats liver (group 1) 
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Fig. 5: Histopathological photomicrograph in the experimental rats liver (group 2) 
 
 
Fig. 6: Histopathological photomicrograph in the experimental rats liver (group 3) 
 
 
Fig. 7: Histopathological photomicrograph in the experimental rats liver (group 4) 
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Fig. 8: Histopathological photomicrograph in the experimental rats liver (group 
 
DISCUSSION 
Hepatoprotective activity of L-arginine was evaluated in 
paracetamol treated albino Wistar rats. The activity was 
assessed by measuring serum marker enzymes, bilirubin, 
alkaline phosphate and histopathological changes in the 
liver. Enhanced levels of serum marker enzymes, bilirubin, 
and alkaline phosphate are an indication of liver damage. 
Paracetamol is a well-known analgesic and antipyretic 
drug moiety, but an overdose of this may produce 
centrilobular hepatic necrosis. More than 90% of the 
Paracetamol is excreted out after 
glucuronidation/sulfation and a small amount undergoes 
metabolism by cytochrome P450 enzyme to form reactive 
intermediate N-acetyl-p-benzoquinone amine. This 
intermediate is readily detoxified by GSH, but the 
saturation of glucuronidation/sulfation occurs when 
paracetamol is administered at higher doses. This leads to 
excessive production of N-acetyl-p-benzoquinone amine, 
which in turn deplete the GSH completely and binds to 
proteins to form adducts. These adduct cause impairment 
in the function of cellular proteins. The overdose of 
paracetamol may also lead to lipid peroxidation and 
pyridine nucleotide oxidation, which may induce liver. 
In the present study, significant hepatic damage was 
observed in the toxicant group (group 2, paracetamol) 
animals as evidenced by the elevated levels of serum 
markers. The alteration in levels reflects the structural 
integrity of hepatocytes. An enhanced Serum glutamic 
oxaloacetic transaminase (SGOT) level is usually 
associated with increased levels of Serum glutamic pyruvic 
transaminase (SGPT) and conversion of amino acids to 
keto acids is effected by an enhanced level of these 
enzymes. The treatment with formulations containing L-
arginine equivalent to 50mg and 100 mg; significantly 
lowered the level of SGPT and SGOT and it indicates that 
formulations are able to protect the cell membrane 
integrity of liver. The synthesis of SALP gets increased due 
to enhanced biliary pressure. Both formulations containing 
L-arginine equivalent to 50mg and 100 mg significantly 
reduced the levels of SALP and bilirubin compare to the 
positive control group. Improvement in the hepatic 
secretory mechanisms IS clearly indicates the effective 
control of SALP and bilirubin levels by L-arginine 
formulations. Both formulations containing L-arginine 
equivalent to 50mg and 100 mg enhanced serum protein 
levels and reduced liver weight in their respective groups. 
Histopathological studies also supported the 
hepatoprotective effect of both formulations, containing L-
arginine equivalent to 50mg and 100 mg. Histopathological 
studies also supported the results observed by biochemical 
studies where L-arginine administration for reduced the 
hepatic injury score of inflammation, apoptosis and 
necrosis. Oral administration of L-arginine significantly 
improved hepatic injury. Hestopathographsalso indicated 
that L-arginine improved the resistance of hepatic cells to 
be damaged by toxic dose of paracetamol. Improved level 
of Nitric oxide (NO) produced by L-arginine may play an 
important role in the metabolism as well as removal of 
paracetamol. 
The liver section of toxicant animals showed degenerative 
changes, aggregates of mononuclear inflammatory cells 
with congested sinusoids. Treatment with formulations 
containing L-arginine equivalent to 50mg and 100 mg 
helped in regaining the normal hepatic architecture. 
Reduction in the levels of SGPT and SGOT reflects the 
stabilization of plasma membrane and the repair of hepatic 
tissue. An elevated level of liver wt, serum marker 
enzymes, and total bilirubin was observed in paracetamol 
treated group 1. Both formulations containing L-arginine 
equivalent to 50mg and 100 mg significantly altered the 
levels of all the parameters and almost brought back to the 
normal level. Possible mechanisms responsible for 
hepatoprotective effect maybe free radical scavenging and 
intercepting those radicals involved in the metabolism of 
paracetamol. The histopathological changes associated 
with the hepatoprotective activity of both the formulations 
containing L-arginine equivalent to 50mg and 100 mg 
support the result of biochemical estimations. 
CONCLUSION 
The toxic dose of paracetamol enhanced the SGPT, SGOT, 
ALP and bilirubin levels. Treatment with silymarin as 
standard and L-arginine as test drugs shows a significant 
decrease in the levels of biochemical markers to the near 
normal levels as compared with the control group. 
Histopathological studies also supported the 
hepatoprotective effect, containing L-arginine. The liver 
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section of toxicant animals showed degenerative changes, 
aggregates of mononuclear inflammatory cells while 
treatment with formulations containing L-arginine helped 
in regaining the normal hepatic architecture.Hence, results 
observed during present work indicated that, 
administration of L-arginine amino acid showed significant 
hepatoprotective and hepatocurative effects against 
paracetamol induced induced hepatotoxicity in rats. 
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